Semax 10mg Peptide

Chemical diagram for Semax by User:Innerstream – Own work, Public Domain, https://commons.wikimedia.org/w/index.php?curid=136526748

KEY SPECIFICATIONS

PRODUCT OVERVIEW

Semax is a synthetic analog of the ACTH(4-10) fragment engineered for enhanced metabolic stability through C-terminal Pro-Gly-Pro modification. This heptapeptide overcomes the short half-life of native ACTH fragments while preserving neurotrophic activity. Research demonstrates potent modulation of neurotrophin expression (BDNF, NGF) and gene transcription programs supporting neuroprotection, neurogenesis, and synaptic plasticity. The PGP extension protects against exopeptidase degradation, enabling efficient blood-brain barrier penetration in experimental models. BIONIX supplies Semax with ≥99% purity for neurobiological and neuroprotective research applications.

MECHANISM OF ACTION

Semax operates through complex mechanisms encompassing rapid signal transduction and long-term transcriptional changes. The peptide modulates neurotrophic factor expression and system-wide neuronal network activities through melanocortin receptor-mediated pathways.

Neurotrophin Modulation:

Semax upregulates critical neurotrophic factors in hippocampus and frontal cortex:

Proposed Signaling Pathway:

Semax Binding → Melanocortin Receptor Activation → cAMP/PKA Cascade → 
CREB Phosphorylation → BDNF/NGF Gene Transcription

Structural Architecture:

The Pro-Gly-Pro tripeptide confers exceptional stability against proteolytic degradation, extending half-life and improving bioavailability compared to unmodified ACTH fragments.

Network-Level Effects: Experimental imaging studies demonstrate modulation of resting-state network behavior, particularly the Default Mode Network (DMN)—brain regions active at rest associated with episodic memory and cognitive processing.

Immune and Vascular Modulation: In focal brain ischemia models, genome-wide analysis revealed Semax induces specific expression changes in immune- and vascular system-related gene sets. Neuroprotective effects appear partially mediated through inflammatory response modulation and vascular repair processes.

Comparative Profile:

RESEARCH APPLICATIONS

Neurotrophin Gene Regulation: Investigation of time-dependent BDNF and NGF expression in hippocampal and cortical tissues. Semax exposure demonstrates rapid, sustained upregulation of neurotrophin mRNA levels essential for neuronal survival, axonal growth, and synaptic plasticity—providing insights into learning and memory molecular mechanisms.

Neuronal Network Dynamics: fMRI studies analyzing resting-state network activities, particularly Default Mode Network modulation. Research examines functional connectivity changes and relationships between peptide exposure and global brain network organization.

Ischemia and Neuroprotection: Focal brain ischemia models investigating infarct volume reduction, neuronal integrity preservation under hypoxic conditions, and regulation of immune response and vascularization gene sets. Genome-wide transcriptional analyses demonstrate specific gene regulation associated with tissue protection and vascular integrity.

Oxidative Stress Research: Studies on lipid peroxidation markers, antioxidant defense mechanism activation, and mitigation of cellular damage from free radicals in stress models.

Cognitive Function Models: Analysis of attention, learning, and memory consolidation mechanisms through BDNF-mediated synaptic plasticity enhancement.

Vascular Repair Studies: Investigation of endothelial function, vascular integrity maintenance, and angiogenic signaling following ischemic events.

ANALYTICAL VERIFICATION

BIONIX Semax undergoes comprehensive analytical characterization:

• HPLC Analysis: ≥99% purity confirmation via optimized chromatographic separation
• Mass Spectrometry: Molecular weight verification (813.93 g/mol) and sequence confirmation
• Amino Acid Analysis: Met-Glu-His-Phe-Pro-Gly-Pro quantification
• Endotoxin Testing: Laboratory quality assurance
• Stability Assessment: Pro-Gly-Pro extension verification

Physical Characteristics:

DEVELOPMENT STATUS

Semax has distinct regulatory history and current status:

• Origin: Developed at Institute of Molecular Genetics, Russian Academy of Sciences (1990s)
• Russia Status: Approved medication for specific neurological conditions; clinical use since 1990s
• FDA Status: Not approved; research compound only
• EMA Status: Not approved; research compound only
• Global Status: Research use only in most jurisdictions
• WADA Classification: Research compound (verify current prohibited list)

BIONIX Semax is supplied exclusively for laboratory research purposes—not for therapeutic use, human administration, veterinary, or clinical applications.

FREQUENTLY ENCOUNTERED INQUIRIES

What is Semax’s mechanism of action?
Semax operates primarily through neurotrophin modulation—upregulating BDNF and NGF gene expression in hippocampus and frontal cortex. The proposed pathway involves melanocortin receptor activation, cAMP/PKA cascade signaling, CREB phosphorylation, and subsequent neurotrophic gene transcription. Additionally, Semax influences resting-state network dynamics (particularly Default Mode Network) and modulates immune/vascular gene expression in ischemia models.

How does Semax differ from Selank?
Both are Russian-developed heptapeptides with Pro-Gly-Pro stability extensions, but derive from different parent molecules with distinct mechanisms. Semax is an ACTH(4-10) analog targeting BDNF/NGF neurotrophin pathways (neuroprotective/cognitive focus). Selank is a Tuftsin analog targeting GABA-A receptors and enkephalinase (anxiolytic/immunomodulatory focus). They represent complementary research tools for different CNS investigation domains.

What is the significance of the Pro-Gly-Pro extension?
The C-terminal Pro-Gly-Pro sequence protects against rapid exopeptidase degradation that destroys native ACTH fragments within minutes. This structural modification dramatically extends half-life, improves bioavailability, and enables efficient blood-brain barrier penetration in experimental models—critical for sustained physiological interactions in research settings.

What are the primary research applications?
Neurotrophin gene regulation studies (BDNF/NGF expression), neuronal network dynamics and fMRI investigations, focal brain ischemia and neuroprotection models, oxidative stress and antioxidant defense research, cognitive function and synaptic plasticity studies, and vascular repair mechanism analyses. All applications limited to controlled laboratory environments.

What storage conditions are required?
Lyophilized powder requires -20°C storage for long-term stability (up to 24 months). Protect from moisture, light, and UV exposure. Post-reconstitution, store at 2-8°C and use within 7-10 days. For extended storage, prepare single-use aliquots and freeze at -20°C, thawing only once per aliquot. Avoid repeated freeze-thaw cycles.

Is Semax approved for clinical use?
Semax is approved in Russia as a medication for specific neurological conditions and has been in clinical use since the 1990s. It is not FDA or EMA approved and is available exclusively for laboratory research in Western markets. BIONIX supplies research-grade material for laboratory use only—not for human therapeutic application.

REFERENCES

• PMID: 25242422 — BDNF/NGF expression changes in rat hippocampus (Dokl Biol Sci, 2014)
• PMID: 28214594 — Resting-state fMRI and Default Mode Network modulation (Front Neurosci, 2017)
• PMID: 23452621 — Immune system and vascularization gene regulation in ischemia (BMC Genomics, 2013)
• PMID: 15742583 — Hepatic biomarkers and lipid peroxidation effects (Bull Exp Biol Med, 2005)
• PMID: 22295571 — Time-dependent BDNF upregulation in cortical tissue (Dokl Biol Sci, 2012)
• Preclinical Studies — Neuroprotective effects and cognitive enhancement models